Zhenpo Zhang

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms.

SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms.

Journal: Frontiers in pharmacology

Published: March 30, 2026

Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database.

Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database.

Journal: Journal of pharmaceutical policy and practice

Published: July 10, 2025

Peripheral neuropathies induced by BRAF+MEK inhibitor combinations: a real-world study based on FAERS database 2011-2022.

Peripheral neuropathies induced by BRAF+MEK inhibitor combinations: a real-world study based on FAERS database 2011-2022.

Journal: Expert opinion on drug safety

Published: July 04, 2025

Real-world pharmacovigilance study on neonatal congenital anomalies associated with maternal drug exposure using the FDA Adverse Event Reporting System.

Real-world pharmacovigilance study on neonatal congenital anomalies associated with maternal drug exposure using the FDA Adverse Event Reporting System.

Journal: Therapeutic advances in drug safety

Published: June 23, 2025

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.

Journal: Endocrine connections

Published: April 12, 2025

Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database.

Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database.

Journal: Expert opinion on drug safety

Published: December 13, 2024

Neurological drugs induced congenital anomalies: A pharmacovigilance analysis of neonatal reports in the FDA adverse event reporting system (FAERS).

Neurological drugs induced congenital anomalies: A pharmacovigilance analysis of neonatal reports in the FDA adverse event reporting system (FAERS).

Journal: Journal of affective disorders

Published: October 28, 2024

Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.

Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.

Journal: Expert opinion on drug safety

Published: October 02, 2024

Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System.

Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System.

Journal: Therapeutic advances in drug safety

Published: September 25, 2024

Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS).

Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS).

Journal: Archives of women's mental health

Published: August 09, 2024

Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

Journal: BMC cancer

Published: August 06, 2024

Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.

Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.

Journal: Endocrine connections

Published: August 06, 2024

Showing 1-12 of 14

Last Updated: 09/26/2026